Advertisement

Postpartum Hemorrhage: What’s New?

  • John C. MarkleyEmail author
  • Daniela A. Carusi
High-risk Obstetrics (T McElrath, Section Editor)
  • 21 Downloads
Part of the following topical collections:
  1. Topical Collection on High Risk Obstetrics

Abstract

Purpose of Review

Postpartum hemorrhage (PPH) remains an important cause of maternal morbidity and mortality in the USA and in particular worldwide. Recent epidemiological studies have enhanced our ability to identify risk factors for PPH. Novel diagnostic, surgical, and pharmaceutical techniques present opportunities for improving our care of patients with PPH.

Recent Findings

This review aims to highlight recent primary research in the field of PPH. Large studies have refuted some assumed risk factors for PPH, including high body mass index and scheduled repeat cesarean delivery. Non-white race is an increasingly important risk factor for major maternal morbidity in the USA. New studies evaluated the role of tranexamic acid, point-of-care tests such as rotational thromboelastometry, uterotonic agents, and cell salvage in the management of PPH.

Summary

Attention to and preparation for PPH, especially in patients with significant risk factors, may allow early intervention and improved patient outcomes. Obstetric units should have protocols that use uterotonic agents for PPH prevention and treatment, and tranexamic acid for treatment only. Centers treating the highest risk patients may benefit from having point-of-care testing and cell salvage available.

Keywords

Postpartum hemorrhage Obstetric hemorrhage Quantitative blood loss Cell salvage Rotational thromboelastometry Tranexamic acid 

Notes

Compliance with Ethical Standards

Conflict of Interest

John C. Markley, MD, PhD, and Daneila A. Carusi, MD, MSc, declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Berg CJ, Harper MA, Atkinson SM, Bell EA, Brown HL, Hage ML, et al. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol. 2005;106(6):1228–34.  https://doi.org/10.1097/01.AOG.0000187894.71913.e8.CrossRefPubMedGoogle Scholar
  2. 2.
    D’Alton ME, Main EK, Menard MK, Levy BS. The National Partnership for Maternal Safety. Obstet Gynecol. 2014;123(5):973–7.  https://doi.org/10.1097/AOG.0000000000000219.CrossRefPubMedGoogle Scholar
  3. 3.
    Main EK, Goffman D, Scavone BM, Low LK, Bingham D, Fontaine PL, et al. National Partnership for Maternal Safety: consensus bundle on obstetric hemorrhage. Obstet Gynecol. 2015;126(1):155–62.  https://doi.org/10.1097/AOG.0000000000000869.CrossRefPubMedGoogle Scholar
  4. 4.
    Dilla AJ, Waters JH, Yazer MH. Clinical validation of risk stratification criteria for peripartum hemorrhage. Obstet Gynecol. 2013;122(1):120–6.  https://doi.org/10.1097/AOG.0b013e3182941c78.CrossRefPubMedGoogle Scholar
  5. 5.
    Patterson JA, Nippita T, Randall DA, Irving DO, Ford JB. Obstetric Transfusion Steering G. Outcomes of subsequent pregnancy following obstetric transfusion in a first birth. PLoS One [Electronic Resource]. 2018;13(9):e0203195.CrossRefGoogle Scholar
  6. 6.
    Butwick AJ, Abreo A, Bateman BT, Lee HC, El-Sayed YY, Stephansson O, et al. Effect of maternal body mass index on postpartum hemorrhage. Anesthesiology. 2018;128(4):774–83.  https://doi.org/10.1097/ALN.0000000000002082.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ahmadzia HK, Phillips JM, James AH, Rice MM, Amdur RL. Predicting peripartum blood transfusion in women undergoing cesarean delivery: a risk prediction model. PLoS One [Electronic Resource]. 2018;13(12):e0208417.CrossRefGoogle Scholar
  8. 8.
    Curtin SC, Gregory KD, Korst LM, Uddin SF. Maternal Morbidity for Vaginal and Cesarean Deliveries, According to Previous Cesarean History: New Data From the Birth Certificate, 2013. Natl Vital Stat Rep 2015;64(4):1–13,Google Scholar
  9. 9.
    Healy DL, Breheny S, Halliday J, Jaques A, Rushford D, Garrett C, et al. Prevalence and risk factors for obstetric haemorrhage in 6730 singleton births after assisted reproductive technology in Victoria Australia. Hum Reprod. 2010;25(1):265–74.  https://doi.org/10.1093/humrep/dep376.CrossRefPubMedGoogle Scholar
  10. 10.
    Park HS, Kwon H, McElrath TF. Assisted reproductive technology and the risk of unplanned peripartum hysterectomy: analysis using propensity score matching. Hum Reprod. 2018;33:1466–73.  https://doi.org/10.1093/humrep/dey228.CrossRefGoogle Scholar
  11. 11.
    Sabban H, Zakhari A, Patenaude V, Tulandi T, Abenhaim HA. Obstetrical and perinatal morbidity and mortality among in-vitro fertilization pregnancies: a population-based study. Arch Gynecol Obstet. 2017;296(1):107–13.  https://doi.org/10.1007/s00404-017-4379-8.CrossRefPubMedGoogle Scholar
  12. 12.
    Le Ray C, Pelage L, Seco A, Bouvier-Colle MH, Chantry AA, Deneux-Tharaux C, et al. Risk of severe maternal morbidity associated with in vitro fertilisation: a population-based study. BJOG Int J Obstet Gynaecol. 2019;126(8):1033–41.Google Scholar
  13. 13.
    Ginstrom Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: increased risks in programmed cycles. Am J Obstet Gynecol. 2019;221(2):126 e1–e18.  https://doi.org/10.1016/j.ajog.2019.03.010.CrossRefGoogle Scholar
  14. 14.
    Nyflot LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Risk factors for severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth. 2017;17(1):17.  https://doi.org/10.1186/s12884-016-1217-0.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK. Racial and ethnic disparities in the incidence of severe maternal morbidity in the United States, 2012-2015. Obstet Gynecol. 2018;132(5):1158–66.  https://doi.org/10.1097/AOG.0000000000002937.CrossRefPubMedGoogle Scholar
  16. 16.
    • Gyamfi-Bannerman C, Srinivas SK, Wright JD, Goffman D, Siddiq Z, D’Alton ME, et al. Postpartum hemorrhage outcomes and race. Am J Obstet Gynecol. 2018;219(2):185 e1–e10.  https://doi.org/10.1016/j.ajog.2018.04.052 The authors used the National Inpatient Sample Database to show that black women in the USA are at a higher risk for severe hemorrhagic morbidity than other ethnic groups, even after controlling for comorbidity. This and similar studies have called on the medical system to examine and mitigate disparities in treatment and access to care based on race. CrossRefGoogle Scholar
  17. 17.
    Booker WA, Gyamfi-Bannerman C, Sheen JJ, Wright JD, Siddiq Z, D’Alton ME, et al. Maternal outcomes by race for women aged 40 years or older. Obstet Gynecol. 2018;132(2):404–13.  https://doi.org/10.1097/AOG.0000000000002751.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hamm RF, Wang E, Romanos A, O’Rourke K, Srinivas SK. Implementation of quantification of blood loss does not improve prediction of hemoglobin drop in deliveries with average blood loss. Am J Perinatol. 2018;35(2):134–9.CrossRefGoogle Scholar
  19. 19.
    Diaz V, Abalos E, Carroli G. Methods for blood loss estimation after vaginal birth. Cochrane Database Syst Rev. 2018;9:CD010980.PubMedGoogle Scholar
  20. 20.
    Girault A, Deneux-Tharaux C, Sentilhes L, Maillard F, Goffinet F. Undiagnosed abnormal postpartum blood loss: incidence and risk factors. PLoS One [Electronic Resource]. 2018;13(1):e0190845.CrossRefGoogle Scholar
  21. 21.
    Borovac-Pinheiro A, Pacagnella RC, Puzzi-Fernandes C, Cecatti JG. Case-control study of shock index among women who did and did not receive blood transfusions due to postpartum hemorrhage. Int J Gynaecol Obstet. 2018;140(1):93–7.CrossRefGoogle Scholar
  22. 22.
    Lee SY, Kim HY, Cho GJ, Hong SC, Oh MJ, Kim HJ. Use of the shock index to predict maternal outcomes in women referred for postpartum hemorrhage. Int J Gynaecol Obstet. 2019;144(2):221–4.CrossRefGoogle Scholar
  23. 23.
    Huissoud C, Carrabin N, Benchaib M, Fontaine O, Levrat A, Massignon D, et al. Coagulation assessment by rotation thromboelastometry in normal pregnancy. Thromb Haemost. 2009;101(4):755–61.CrossRefGoogle Scholar
  24. 24.
    Armstrong S, Fernando R, Ashpole K, Simons R, Columb M. Assessment of coagulation in the obstetric population using ROTEM(R) thromboelastometry. Int J Obstet Anesth. 2011;20(4):293–8.  https://doi.org/10.1016/j.ijoa.2011.05.004.CrossRefPubMedGoogle Scholar
  25. 25.
    de Lange NM, van Rheenen-Flach LE, Lance MD, Mooyman L, Woiski M, van Pampus EC, et al. Peri-partum reference ranges for ROTEM(R) thromboelastometry. Br J Anaesth. 2014;112(5):852–9.  https://doi.org/10.1093/bja/aet480.CrossRefPubMedGoogle Scholar
  26. 26.
    Lee J, Eley VA, Wyssusek KH, Coonan E, Way M, Cohen J, et al. Baseline parameters for rotational thromboelastometry (ROTEM(R)) in healthy women undergoing elective caesarean delivery: a prospective observational study in Australia. Int J Obstet Anesth. 2019;38:10–8.  https://doi.org/10.1016/j.ijoa.2019.01.008.CrossRefPubMedGoogle Scholar
  27. 27.
    Toffaletti JG, Buckner KA. Use of earlier-reported rotational thromboelastometry parameters to evaluate clotting status, fibrinogen, and platelet activities in postpartum hemorrhage compared to surgery and intensive care patients. Anesth Analg. 2019;128(3):414–23.  https://doi.org/10.1213/ANE.0000000000003499.CrossRefPubMedGoogle Scholar
  28. 28.
    Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015;70(2):166–75.  https://doi.org/10.1111/anae.12859.CrossRefPubMedGoogle Scholar
  29. 29.
    McNamara H, Kenyon C, Smith R, Mallaiah S, Barclay P. Four years’ experience of a ROTEM((R)) -guided algorithm for treatment of coagulopathy in obstetric haemorrhage. Anaesthesia. 2019;74(8):984–91.  https://doi.org/10.1111/anae.14628.CrossRefPubMedGoogle Scholar
  30. 30.
    Snegovskikh D, Souza D, Walton Z, Dai F, Rachler R, Garay A, et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth. 2018;44:50–6.CrossRefGoogle Scholar
  31. 31.
    Schenk B, Gorlinger K, Treml B, Tauber H, Fries D, Niederwanger C, et al. A comparison of the new ROTEM((R)) sigma with its predecessor, the ROTEMdelta. Anaesthesia. 2019;74(3):348–56.  https://doi.org/10.1111/anae.14542.CrossRefPubMedGoogle Scholar
  32. 32.
    Gill P, Patel A, Van Hook MJ. Uterine Atony. StatPearls. Treasure Island (FL) 2019.Google Scholar
  33. 33.
    Adnan N, Conlan-Trant R, McCormick C, Boland F, Murphy DJ. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. BMJ. 2018;362:k3546.CrossRefGoogle Scholar
  34. 34.
    Charles D, Anger H, Dabash R, Darwish E, Ramadan MC, Mansy A, et al. Intramuscular injection, intravenous infusion, and intravenous bolus of oxytocin in the third stage of labor for prevention of postpartum hemorrhage: a three-arm randomized control trial. BMC Pregnancy Childbirth. 2019;19(1):38.CrossRefGoogle Scholar
  35. 35.
    Widmer M, Piaggio G, Nguyen TMH, Osoti A, Owa OO, Misra S, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379(8):743–52.  https://doi.org/10.1056/NEJMoa1805489.CrossRefPubMedGoogle Scholar
  36. 36.
    Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2018;12:CD011689.PubMedGoogle Scholar
  37. 37.
    Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2019;4:CD001808.PubMedGoogle Scholar
  38. 38.
    Abd El Aziz MA, Iraqi A, Abedi P, Jahanfar S. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. System Rev. 2018;7(1):170.CrossRefGoogle Scholar
  39. 39.
    Khan KS, Moore PAS, Wilson MJ, Hooper R, Allard S, Wrench I, et al. Cell salvage and donor blood transfusion during cesarean section: a pragmatic, multicentre randomised controlled trial (SALVO). PLoS Med. 2017;14(12):e1002471.  https://doi.org/10.1371/journal.pmed.1002471.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yan H, Hu LQ, Wu Y, Fan Q, Wong CA, McCarthy RJ. The association of targeted cell salvage blood transfusion during cesarean delivery with allogeneic packed red blood cell transfusions in a maternity hospital in China. Anesth Analg. 2018;127(3):706–13.  https://doi.org/10.1213/ANE.0000000000003303.CrossRefPubMedGoogle Scholar
  41. 41.
    McLoughlin C, Roberts TE, Jackson LJ, Moore P, Wilson M, Hooper R, et al. Cost-effectiveness of cell salvage and donor blood transfusion during caesarean section: results from a randomised controlled trial. BMJ Open. 2019;9(2):e022352.  https://doi.org/10.1136/bmjopen-2018-022352.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lim G, Melnyk V, Facco FL, Waters JH, Smith KJ. Cost-effectiveness analysis of intraoperative cell salvage for obstetric hemorrhage. Anesthesiology. 2018;128(2):328–37.  https://doi.org/10.1097/ALN.0000000000001981.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    •• Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16.  https://doi.org/10.1016/S0140-6736(17)30638-4 Exploratory analyses of WOMEN trial dataset that excluded early mortality deaths at increasing time intervals after randomization. These authors concluded that the effect of tranexamic acid for treatment of PPH is likely more profound than the WOMAN trial stated. CrossRefGoogle Scholar
  44. 44.
    Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018;2:CD012964.PubMedGoogle Scholar
  45. 45.
    WHO. WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; 2017.Google Scholar
  46. 46.
    California Maternal Quality Care Collaborative. Tranexamic acid (TXA) for obstetric hemorrhage. 2017. https://www.cmqcc.org/sites/default/files/TXA%20Recommendations%20FINAL%20%207.24.17.pdf. Accessed 13 September 2019.
  47. 47.
    • Sentilhes L, Winer N, Azria E, Senat MV, Le Ray C, Vardon D, et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med. 2018;379(8):731–42 A large multiinstitutional, randomized, double-blind, placebo-controlled trial demonstrating no significant difference between prophylactic tranexamic acid and placebo for the prevention of PPH after vaginal delivery. CrossRefGoogle Scholar
  48. 48.
    Abbas AM, Shady NW, Sallam HF. Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. J Gynecol Obstet Hum Reprod. 2019;48(2):115– 631.CrossRefGoogle Scholar
  49. 49.
    Ker K, Roberts I, Chaudhri R, Fawole B, Beaumont D, Balogun E, et al. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials [Electronic Resource]. 2018;19(1):712.Google Scholar
  50. 50.
    Shady NW, Sallam HF, Elsayed AH, Abdelkader AM, Ali SS, Alanwar A, et al. The effect of prophylactic oral tranexamic acid plus buccal misoprostol on blood loss after vaginal delivery: a randomized controlled trial. J Matern Fetal Neonatal Med. 2019;32(11):1806–12.CrossRefGoogle Scholar
  51. 51.
    Zargar M, Nikbakht R, Ahmadi M. The effect of tranexamic acid on preventing post-partum hemorrhage due to uterine atony: a triple-blind randomized clinical trial. Curr Clin Pharmacol. 2018;13(2):136–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Anesthesia and Perioperative Care, Zuckerberg San Francisco General Hospital and Trauma CenterUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of Obstetrics and Gynecology, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations